T. Rowe Price Associates
CNTB

T. Rowe Price Associates’s Connect Biopharma Holdings CNTB Stock Holding History

T. Rowe Price Associates’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30K Buy
+12,469
New +$30.2K ﹤0.01% 3212

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

T. Rowe Price Associates's CNTB Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Connect Biopharma Holdings (CNTB) in Q2 2026: 12,469 shares worth $30K. The stake represents ﹤0.01% of the portfolio and ranks #3212 among its holdings.

56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • T. Rowe Price Associates held 12,469 shares of Connect Biopharma Holdings worth $30K as of Q2 2026.
  • Connect Biopharma Holdings was a new T. Rowe Price Associates position in Q2 2026.
  • Connect Biopharma Holdings made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3212 holding.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.